Respiratory tract neoplasm

Researchers are testing a new cell therapy called CRTKVA11-03 in people with advanced solid tumors that carry a specific KRAS G12V mutation and a matching immune marker called HLA-A*11:01. The treatment uses each patient's own T cells, engineered to recognize and attack cancer ce…

This Phase 3 trial tests whether adding an experimental mRNA vaccine (V940) to standard immunotherapy (Keytruda) can prevent non-small cell lung cancer from coming back after surgery. About 868 people with stage II-IIIB lung cancer who have had their tumors completely removed wil…

This trial tests a vaccine made from lung cancer cells, combined with an immune-boosting drug (N-803), in people who have had surgery for non-small cell lung cancer (NSCLC) that is PD-L1 negative. The goal is to see if the vaccine can train the immune system to destroy any remain…

This early-phase trial is testing whether combining two drugs—vismodegib and atezolizumab—is safe and tolerable for people with advanced non-small cell lung cancer that has returned or spread. Vismodegib blocks certain enzymes that help cancer cells grow, while atezolizumab helps…

This study tests whether adding local treatments like surgery or radiation to a combination of two immunotherapy drugs (nivolumab and ipilimumab) helps people with stage IV non-small cell lung cancer live longer compared to immunotherapy alone. About 339 participants who have not…

This study tests whether adding an inhaled form of the drug azacytidine to standard chemotherapy and immunotherapy (durvalumab) can improve outcomes for people with early-stage non-small cell lung cancer before they have surgery. The trial involves 60 adults with operable stage I…

This study looks at whether adding surgery or radiation to the targeted drug osimertinib helps people with advanced EGFR-mutant non-small cell lung cancer live longer without their cancer growing. About 173 participants will receive either osimertinib alone or osimertinib plus lo…

This early-stage trial tests a personalized cell therapy (TIL injection) for people with advanced solid tumors that have spread or come back. The treatment uses the patient's own immune cells, grown in a lab, to fight the cancer. The main goal is to check safety, and the study wi…

This early-stage trial tests a new drug called denikitug, alone or with another drug (zimberelimab), in 416 adults with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety, find the best dose, and see if the drugs shrink tumors…

This phase III trial compares an experimental drug called YL201 with standard chemotherapy in people whose nasopharyngeal carcinoma has returned or spread and no longer responds to PD-(L)1 inhibitors and at least two prior chemotherapy regimens. About 400 participants will receiv…

This study tests a new drug called SKB264 in people with advanced solid tumors that have not responded to standard therapies. The drug is an antibody-drug conjugate designed to deliver chemotherapy directly to cancer cells. The trial includes over 1,400 participants with various …

This early-stage trial tests whether combining two drugs, ceritinib and nivolumab, is safe and effective for people with a specific genetic subtype of advanced lung cancer called ALK-positive NSCLC. About 57 adults with stage IIIB or IV disease will receive the combination. The m…

This study tests a new drug called ARV-806 in adults with advanced solid tumors that have a specific KRAS G12D mutation. The drug aims to break down the mutated protein that helps tumors grow. The trial has two parts: first, finding a safe dose in small groups, then testing that …

This phase 3 trial compares a new drug, divarasib, to two existing targeted therapies (sotorasib and adagrasib) in 338 people with advanced or metastatic non-small cell lung cancer that has a specific KRAS G12C mutation and has progressed after prior treatment. Participants take …

This study tests whether giving a higher radiation dose directly to the tumor, while keeping the standard dose to surrounding healthy tissue, can improve outcomes for people with stage II to IIIB non-small cell lung cancer. About 146 participants will receive either photon (IMRT)…

This study tests whether adding tocilizumab (a drug used for arthritis) to standard immunotherapy can reduce severe side effects in people with advanced melanoma, lung cancer, or bladder cancer. About 35 participants will receive all three drugs. The goal is to see if the combina…

This early-stage trial is testing an experimental drug called belzutifan in people with advanced solid tumors that have not responded to standard treatments. Belzutifan works by blocking a protein (HIF-2α) that tumors use to survive in low-oxygen conditions. The main goal is to f…

This study tests the safety and best dose of adding telaglenastat to the standard drug osimertinib for people with stage IV non-small cell lung cancer that has a specific EGFR mutation. The two drugs work together to block enzymes that cancer cells need to grow. The trial involve…

This study tests an experimental drug called REGN5093 in people with advanced non-small cell lung cancer that has a specific change in the MET gene. The first part finds a safe dose, and the second part checks if the drug can shrink tumors. About 231 participants will take part.

This study tests three drugs—durvalumab (an immunotherapy), olaparib (a DNA repair blocker), and cediranib (a blood vessel growth blocker)—in different combinations for people with advanced solid tumors, especially ovarian cancer. The phase 1 part finds safe doses, and the phase …

This phase 2 trial tests a new drug called THIO, which targets telomeres in cancer cells, followed by the immunotherapy cemiplimab (LIBTAYO) in people with advanced non-small cell lung cancer. The study includes about 227 participants whose cancer has progressed after initial tre…

This phase 2 trial tests a combination of three types of drugs—an immunotherapy (pembrolizumab), a targeted therapy (lenvatinib), and chemotherapy (pemetrexed plus cisplatin or carboplatin)—as a first treatment for people with advanced malignant pleural mesothelioma that cannot b…

This early-phase trial tests a new drug called BI 764532 (obrixtamig) added to standard chemotherapy and immunotherapy for people with extensive-stage small cell lung cancer. The main goal is to find the highest safe dose of BI 764532 when given with standard treatments. About 46…

This early-phase trial tests a new drug called BI 764532 (Obrixtamig) given together with standard chemotherapy for people with advanced neuroendocrine carcinoma (NEC), a rare and fast-growing cancer. The study involves about 55 adults whose tumors have a specific marker (DLL3). …

This phase 1 trial is testing the safety and best dose of a combination of three drugs—entinostat, nivolumab, and ipilimumab—in people with advanced solid tumors that have spread or cannot be removed. The goal is to see if this mix can help the immune system fight cancer more eff…

This phase II trial tests a new approach for advanced non-small cell lung cancer that hasn't responded to standard treatments. It combines photoimmunotherapy (ASP-1929), a light-activated drug that targets cancer cells, with cemiplimab, an immunotherapy that boosts the immune sys…

This early-stage trial tests a new antibody-like drug called BI 764532 alongside standard chemotherapy in adults with advanced small cell lung cancer that has returned after platinum-based treatment. The main goal is to find a safe dose and check for side effects. About 69 partic…

This Phase 3 study compares a new drug called YL201 to the standard treatment topotecan in 438 adults with relapsed small cell lung cancer. The goal is to see if YL201 helps people live longer. Participants receive either YL201 by infusion every three weeks or topotecan by inject…

This phase 3 trial tests whether adding savolitinib to the standard drug osimertinib helps people with a specific type of advanced lung cancer (EGFR-mutant, MET-positive non-small cell lung cancer). About 412 participants will receive either the combination or a placebo plus osim…

Researchers are testing an experimental oral drug called PhOx430 in people with advanced solid tumors, including glioblastoma and triple-negative breast cancer. The trial has two parts: first, they give increasing doses to small groups to find a safe dose and watch for side effec…

This early-stage trial is testing whether combining valemetostat tosylate with two different antibody-drug conjugates (T-DXd or Dato-DXd) is safe and effective for people with advanced solid tumors. About 210 adults with at least one measurable tumor will receive the drugs orally…

This Phase III trial tests whether giving radiation in three smaller doses (FSRS) works better than a single large dose (SRS) for cancer that has spread to the brain. About 269 adults with lung, breast, melanoma, kidney, or gastrointestinal cancers will be randomly assigned to on…

Researchers are testing an experimental antibody called ONC-392 in people with advanced solid tumors, including non-small cell lung cancer and melanoma. The trial gives ONC-392 alone or with pembrolizumab, an approved immunotherapy, to see what doses are safe and how the body pro…

This Phase 2 trial is testing an experimental drug called BNT327 combined with standard chemotherapy in 110 people with small-cell lung cancer. One group has untreated extensive-stage disease, while others have cancer that returned after prior treatment. The study aims to see if …

This phase III trial compares the standard immunotherapy drug pembrolizumab alone versus pembrolizumab plus radiation therapy in 290 patients with metastatic head and neck cancer. The goal is to see if adding radiation improves overall survival. Participants receive pembrolizumab…

This early-stage trial tests the safety of combining precise radiation (SBRT) with immunotherapy (durvalumab) and two chemotherapy drugs (platinum and etoposide) for people with extensive-stage small cell lung cancer that has stopped responding to platinum chemo. The study aims t…

This study tests whether adding radiation therapy to the usual maintenance drug atezolizumab helps people with extensive-stage small cell lung cancer live longer without their cancer growing. About 138 participants who have already responded to initial chemo-immunotherapy will be…

This study tested a combination of two drugs, veliparib and topotecan, in 88 patients with solid tumors or ovarian cancer that returned after initial treatment. The goal was to find the safest dose and see how well the drugs shrink tumors. While the treatment aims to control the …

This study looks at whether using focused radiation (stereotactic radiosurgery) only on the brain tumors, instead of the whole brain, can help preserve thinking and memory in people with small cell lung cancer that has spread to the brain. About 55 participants will receive this …

This phase III trial is testing whether a precise, high-dose radiation technique called stereotactic radiosurgery (SRS) is better at preserving memory and thinking than the current standard of whole brain radiation that avoids the hippocampus (the brain's memory center) plus a dr…

This study is testing a new robotic surgery system, the da Vinci SP, for removing part or all of a lung (lobectomy) or the thymus gland (thymectomy) in people with lung cancer, benign lung disease, thymoma, or myasthenia gravis. The goal is to see if the robot can perform these s…

This phase II trial tests whether combining two drugs, atezolizumab and bevacizumab, can shrink rare solid tumors like appendix cancer, anal cancer, and mesothelioma. About 133 participants with various rare cancers will receive the drugs intravenously. The goal is to see if the …

This program provides early access to divarasib, an experimental oral drug designed to target the KRAS G12C mutation found in some non-small cell lung cancers. It is open to adults with advanced or metastatic disease that has progressed after at least one prior standard treatment…

This early-phase trial tests whether combining two immunotherapy drugs (ipilimumab and nivolumab) with radiation therapy is safe and effective for patients with stage II or III non-small cell lung cancer that cannot be surgically removed. The study enrolls 21 participants who hav…

This study tests whether adding the targeted therapy cabozantinib to a standard immunotherapy combination (nivolumab and ipilimumab) can better control advanced nasopharyngeal cancer that has returned or spread. About 50 adults whose cancer worsened after platinum chemotherapy an…

This early-stage trial tests a new type of immunotherapy called CD70-targeted CAR-T cells in people with advanced solid tumors, including kidney, lung, ovarian, and thyroid cancers. The treatment involves taking a patient's own immune cells, engineering them to recognize and atta…

This study tests a drug called sacituzumab govitecan combined with pembrolizumab (and sometimes chemotherapy) as a first treatment for people with advanced or metastatic non-small-cell lung cancer that lacks specific genetic changes. About 193 participants will receive these comb…

This early-phase study tests a new drug, RO7247669, that targets two immune system checkpoints (PD-1 and LAG-3) to help the body fight cancer. About 170 adults with advanced solid tumors (including melanoma, lung cancer, and esophageal cancer) who have run out of standard options…

This early study tests whether giving nivolumab (an immunotherapy) along with standard chemotherapy before surgery is safe and feasible for people with malignant pleural mesothelioma. The main goal is to see if this approach delays surgery by more than 30 days. 22 participants wi…

This early-phase trial is testing whether combining two drugs, amivantamab and tepotinib, can help control non-small cell lung cancer with MET alterations. Only 3 adults with advanced disease that cannot be surgically removed are enrolled. The main goal is to check safety and see…

This study tests whether adding the immunotherapy drug nivolumab after surgery and chemotherapy helps prevent non-small cell lung cancer from coming back. About 900 adults with stage IB to IIIA lung cancer who had their tumor completely removed are participating. The goal is to s…

This phase 3 trial tests a daily pill called osimertinib (AZD9291) against a placebo in 682 people with a specific type of lung cancer (EGFR-mutated, stages IB to IIIA) who have had surgery to remove their tumor. The goal is to see if the drug can delay or prevent the cancer from…

This Phase II trial tests whether adding olaparib to durvalumab helps keep stage IV non-small cell lung cancer from growing after initial chemotherapy. About 400 patients whose cancer did not worsen on standard chemo plus durvalumab will receive either the combination or durvalum…

This early-phase trial is testing an experimental drug called TTX-080, which blocks a protein (HLA-G) that tumors use to hide from the immune system. The study will give TTX-080 alone or combined with other cancer drugs (pembrolizumab, cetuximab, or FOLFIRI plus cetuximab) to abo…

This early-stage trial tested the safety and best dose of two drugs, ixabepilone and temsirolimus, given together to adults with advanced solid tumors that had spread or could not be removed. The goal was to find a dose that limits side effects while potentially killing more canc…

This Phase 3 trial is testing a new drug called sacituzumab tirumotecan (MK-2870) against standard platinum-based chemotherapy for people with a specific type of advanced lung cancer (EGFR-mutated non-squamous non-small cell lung cancer) that has worsened despite prior targeted t…

This study tests an experimental drug called TransCon IL-2 β/γ, which aims to boost the immune system to fight cancer. It is given alone or with other treatments like pembrolizumab (Keytruda) or chemotherapy. The trial includes 320 adults with advanced solid tumors that have not …

This study tests two new treatments—cabozantinib alone or with nivolumab—against standard chemotherapy for people with advanced non-squamous lung cancer that has returned. The goal is to see if these combinations can slow cancer growth better than current options. About 117 adult…

This early-phase study is testing a new drug called JZP815 in people with advanced or spreading solid tumors that have specific changes in the MAPK pathway. The main goals are to check the drug's safety, find the right dose, and see if it can shrink tumors. About 332 adults who h…

This study compares a new, potentially more affordable drug called MB12 (a biosimilar to Keytruda) to the original Keytruda, both given with chemotherapy, as a first treatment for people with advanced stage IV non-squamous non-small cell lung cancer. About 726 adults who have not…

This study tests whether a blood test for Epstein-Barr virus (EBV) DNA can help doctors choose the best chemotherapy after standard radiation for nasopharyngeal cancer. About 685 patients will first receive standard chemoradiation. Then, based on whether EBV DNA is still detectab…

This early-phase trial tests a new drug called BAY 1895344 combined with standard chemotherapy (irinotecan or topotecan) in people with advanced solid tumors, especially small cell lung cancer, poorly differentiated neuroendocrine cancer, and pancreatic cancer. The goal is to fin…

This study tested giving the immunotherapy drugs nivolumab (with or without ipilimumab) before surgery to people with a type of lung cancer called non-small-cell lung cancer. The goal was to see if this approach is safe and helps shrink tumors before removal. 39 participants were…

This phase 2 trial tests a combination of three drugs—tiragolumab, atezolizumab, and bevacizumab—in people with advanced non-squamous non-small cell lung cancer that has already been treated. The goal is to see if the combination can shrink tumors or slow disease progression. Abo…

This phase II trial tests whether adding two types of precisely targeted radiation (BgRT and SBRT) to the standard drug osimertinib can better control advanced EGFR-positive lung cancer that has started to grow in a few new spots. About 32 adults with this specific type of lung c…

This early-stage study tests a new drug called GEN1042, which aims to help the immune system fight cancer. It is being tested alone or with other cancer drugs in 42 Japanese adults with advanced solid tumors. The main goal is to check safety and find the right dose.

This study tests a new drug called JDQ443 in people with advanced lung cancer that has a specific genetic change (KRAS G12C mutation) and does not respond well to standard treatments. The drug is taken as a pill and aims to shrink or control the cancer. About 95 participants will…

This phase 3 trial tests whether adding pembrolizumab (an immunotherapy) and olaparib (a targeted drug) to standard chemotherapy and radiation can help people with limited-stage small cell lung cancer live longer. About 672 participants will receive either the drug combo or a pla…

This early-stage trial is testing a new drug called tarlatamab, which helps the immune system find and attack cancer cells, when given together with standard chemotherapy and immunotherapy. The study includes about 184 people with extensive-stage small cell lung cancer who have n…

This Phase 3 trial tests whether a combination of two immunotherapy drugs (acasunlimab and pembrolizumab) works better than the standard chemotherapy docetaxel for people with a specific type of advanced lung cancer (PD-L1 positive NSCLC) that has worsened after prior treatment. …

This phase 2 trial is testing whether giving the immunotherapy drug durvalumab along with standard chemotherapy before surgery or radiation can help people with stage IIB-IIIB non-small cell lung cancer. The study includes 142 participants whose tumors are considered removable or…

This study offers continued treatment with capmatinib for people with advanced solid tumors that depend on a protein called cMET. It includes 29 participants who were already benefiting from capmatinib in a previous Novartis trial. The main goal is to monitor long-term safety and…

This early-phase trial tests two drugs together—MK-2206 and hydroxychloroquine—in people with advanced solid tumors, melanoma, kidney, or prostate cancer. The goal is to find the safest dose and see how the combination affects cancer cell growth. About 62 participants will take b…

This phase I trial tests the drug pazopanib (Votrient) in 54 patients with advanced solid tumors that have spread or not responded to other treatments. Pazopanib works by blocking blood vessel growth that tumors need. Researchers aim to find the best dose that balances effectiven…

This early-phase study tests a new drug called M9466, a PARP1 inhibitor, alone or combined with other drugs in 60 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check safety and how the body processes the drug. Researchers …

This phase 2 trial tests two drugs, erlotinib and cabozantinib, given alone or together in 125 patients with advanced non-small cell lung cancer that does not have a common EGFR mutation. The goal is to see if the combination works better than either drug alone to slow cancer gro…

This phase 3 trial tests whether adding lurbinectedin to atezolizumab as maintenance therapy helps people with extensive-stage small-cell lung cancer live longer without the disease worsening. Participants first receive standard induction chemo-immunotherapy, then those with stab…

This study tests a drug called olaparib in people with advanced cancers (like brain tumors, bile duct cancer, or other solid tumors) that have a specific gene change called IDH1 or IDH2 mutation. The drug works by blocking an enzyme that cancer cells need to grow. About 89 partic…

This phase 3 trial tests whether giving the targeted drug osimertinib (Tagrisso) before surgery, alone or with chemotherapy, works better than standard chemotherapy alone for people with a specific type of lung cancer (EGFR-mutant, non-small cell). About 358 patients with stage I…

This study tests whether adding the drug cediranib to standard chemotherapy (cisplatin and pemetrexed) can help people with malignant pleural mesothelioma, a rare and aggressive lung cancer. In the first phase, researchers found the safest dose of cediranib. In the second phase, …

This phase 2 trial tests a combination of two drugs—ceralasertib (a pill) and durvalumab (an infusion)—in 39 adults with advanced or metastatic non-small cell lung cancer that has worsened after standard treatments like immunotherapy and chemotherapy. The main goal is to see if t…

This phase 3 trial tests whether adding the drug tarlatamab to standard chemotherapy and immunotherapy helps people with extensive-stage small-cell lung cancer live longer. About 330 participants will be randomly assigned to receive either the new combination or standard treatmen…

This early-phase study tests an experimental oral drug (E7727) combined with another oral drug (decitabine) in people with advanced solid tumors that have not responded to at least two prior treatments. The main goals are to find the safest dose and understand side effects. Up to…

This study tests whether combining two targeted drugs, osimertinib and amivantamab, can safely control advanced lung cancer that has a specific EGFR gene mutation. About 60 adults with newly diagnosed or recurrent non-small cell lung cancer that cannot be surgically removed will …

This phase III trial studies whether adding the immunotherapy drug durvalumab to standard chemotherapy and radiation can help people with stage 3 non-small cell lung cancer that cannot be surgically removed. About 660 participants will receive either chemoradiation plus durvaluma…

This phase II trial is testing whether combining the targeted drug trametinib with the chemotherapy docetaxel can shrink tumors in people with advanced KRAS-mutant non-small cell lung cancer. The study enrolls 60 patients whose cancer has worsened after one or two prior treatment…

This early-phase study tests obrixtamig, a drug that helps the immune system attack cancer cells, in adults with advanced small cell lung cancer or other neuroendocrine cancers that have a specific marker called DLL3. Participants receive the drug weekly or every three weeks for …

This early-stage trial tests a new drug called ICT01, a lab-made antibody, in 292 people with advanced cancers that have not responded to standard treatments. The drug is given alone or with another cancer drug (Keytruda). The main goals are to check safety and see if the drug ca…

This early-phase study tests the safety and best dose of a drug called veliparib when given with two chemotherapy drugs (carboplatin and paclitaxel) in people with advanced solid tumors that have spread or can't be removed. It includes patients who also have liver or kidney probl…

This phase II trial tests whether giving cancer drugs based on a tumor's genetic makeup can help people with advanced solid tumors that cannot be removed by surgery or have spread. About 920 participants will receive a drug or drug combination tailored to their tumor's specific g…

This study tests whether adding the experimental drug TRC102 to standard treatment (chemotherapy, radiation, and immunotherapy) can help shrink tumors and extend survival in people with stage III non-squamous lung cancer. TRC102 blocks cancer cells from repairing damage, making t…

This large study is testing several targeted therapies and immunotherapies for people with advanced non-small cell lung cancer. Instead of a tissue biopsy, a simple blood test is used to find specific genetic changes in the cancer. The goal is to see if matching the right drug to…

This study tests a daily pill called adagrasib in 68 patients with a specific type of advanced lung cancer (KRAS G12C mutation) who are either 70 or older or have poor physical health. The goal is to see if the drug can shrink tumors or stop them from growing. Patients take the m…

This study tests whether combining two drugs, savolitinib and durvalumab, can help control advanced lung cancer in people whose tumors have a specific genetic change called MET alteration. About 47 adults in China with non-small cell lung cancer that has spread will receive the c…

This study tests whether adding chemotherapy to the targeted drug osimertinib (Tagrisso) helps people with advanced EGFR-mutated non-small cell lung cancer live longer without their cancer worsening. About 587 adults with newly diagnosed or recurrent advanced lung cancer will be …

This study tests a drug called trastuzumab deruxtecan, alone or with other medicines, in people with advanced solid tumors that have a protein called HER2. The goal is to see if the drug can shrink or control these cancers. About 127 adults with tumors that cannot be removed by s…

This early trial tests a radioactive drug called MNPR-101-PCTA-177Lu in adults with advanced solid tumors, including bladder, breast, lung, and pancreatic cancers. Participants receive three equal doses by IV over two 12-week cycles. The main goal is to find a safe dose and under…

This study tests an experimental drug called LM-108, given alone or with another immunotherapy (toripalimab), in people with advanced solid tumors that have stopped responding to standard treatments. The trial has two phases: first, finding the safest dose, then expanding to see …

This phase 2 trial tests whether adding two drugs (durvalumab and ceralasertib) after standard chemo-immunotherapy can help control extensive-stage small cell lung cancer. About 30 people who have not had prior treatment will receive the combination. The main goal is to see how l…

This early-stage trial tests an experimental mRNA-based cancer vaccine (mRNA-4157) in 161 people with solid tumors. The vaccine is designed to train the immune system to attack cancer cells. Some participants receive the vaccine alone, while others get it with the immunotherapy d…

This study tests a new drug called INCB099280 in 73 people with advanced solid tumors who have not received immunotherapy before. The goal is to see if the drug can shrink tumors and to check for side effects. The study focuses on safety and how well the drug works in the short t…

This phase III trial is testing whether giving chemotherapy and immunotherapy both before and after surgery (perioperative) is better than giving it only after surgery (adjuvant) for people with stage II-IIIB non-small cell lung cancer that can be removed. About 1,100 participant…

This study compares a new drug, BAT3306, to the approved drug Keytruda in people with stage IB-IIIA non-small cell lung cancer whose tumors have been completely removed by surgery. The goal is to see if BAT3306 works similarly as an additional treatment to help keep the cancer fr…

This early-stage trial is testing a new drug, saruparib, in 41 people with advanced solid tumors that have not responded to standard treatments. The main goals are to check the drug's safety, how it interacts with other common medications, and how well different pill versions wor…

This early-phase trial tests a new drug called KQB198 in adults with advanced solid tumors that have not responded to other treatments. The study aims to find a safe dose and see if KQB198 can shrink tumors when used alone or with other cancer drugs. About 100 participants will t…

This early-phase study tests whether a diet very low in vitamin B6 can make immunotherapy work better for people with solid tumors. About 20 adults aged 18-80 will follow this special diet for 6 weeks while continuing their regular immunotherapy. The main goal is to check if the …

This early-stage trial tests FF-10850, a liposome-wrapped version of the chemotherapy drug topotecan, in 96 adults with advanced solid tumors like ovarian, cervical, and Merkel cell carcinoma. The main goals are to find the safest dose and understand side effects. Researchers hop…

This phase 1 trial tests FF-10832, a liposomal version of the chemotherapy drug gemcitabine, in adults with advanced solid tumors, including biliary tract cancer, that have not responded to standard treatment or have no standard options. Researchers give the drug as an intravenou…

This early-phase study tests a new drug called MK-2870, either alone or with the immunotherapy pembrolizumab, in Japanese patients with advanced solid tumors or a type of lung cancer. The main goal is to check the safety and side effects of these treatments. About 30 people will …

This phase 1 trial tests whether combining several investigational immunotherapy drugs, with or without chemotherapy, can safely shrink advanced solid tumors. The study enrolls adults with cancers like non-small-cell lung cancer or triple-negative breast cancer that have progress…

This trial tests whether adding weekly thermotherapy, a treatment that heats the tumor and lymph nodes, to standard radiotherapy can help people with head and neck cancer who cannot receive chemotherapy. The goal is to find a safe dose of thermotherapy that does not cause severe …

This phase I/II trial tests a combination of two drugs given directly into the spinal fluid for people with leptomeningeal metastasis, a condition where cancer spreads to the membranes covering the brain and spinal cord. The drugs are QL1706, a bispecific antibody that blocks two…

This study compares standard radiation plus cisplatin against two experimental approaches: radiation with docetaxel and cetuximab, or radiation with cisplatin and the immunotherapy drug atezolizumab. About 613 patients with high-risk stage III-IV head and neck cancer will partici…

This early-stage trial is testing a new oral drug, PF-07799933, in people aged 16 and older with advanced solid tumors that have a specific BRAF gene change. The drug is given alone or combined with other medicines like binimetinib or cetuximab. The study aims to find safe doses …

This study tests the drug tarlatamab in people with advanced tumors that have a protein called DLL3. The goal is to see if the drug can shrink or control these tumors. About 29 adults with stage IV cancer will receive tarlatamab, and researchers will track how well it works and a…

This study looks at the long-term safety of brigimadlin, a cancer drug taken as tablets, in adults with solid tumours who have already received at least 4 cycles of it in a previous study. About 90 participants will take the drug once every 3 weeks, and doctors will monitor their…

This study tests whether combining two drugs, atezolizumab and cobimetinib, can help people with advanced non-small cell lung cancer whose tumors stopped responding to standard immunotherapy. About 51 adults with metastatic or recurrent lung cancer will receive the combination. T…

This study tests an experimental drug called patritumab deruxtecan in people with advanced non-small cell lung cancer that has a specific EGFR mutation and has stopped responding to other treatments. About 277 participants will receive the drug to see if it shrinks tumors. The go…

This study tests a new drug called BMS-986490, alone or with bevacizumab, in people with advanced solid tumors that have a specific marker (CEACAM5). The goal is to see if the treatment is safe and works against these cancers. About 360 participants will take part in this early-s…

This phase 3 study compares the experimental drug poziotinib to the standard chemotherapy docetaxel in 268 people with advanced non-small cell lung cancer that has a specific HER2 mutation. Participants must have already tried at least one prior treatment. The main goal is to see…

This early-phase study tests a new experimental drug (BI 770371) alone or with another immunotherapy (ezabenlimab) in adults with advanced solid tumors who have run out of standard options. The main goal is to find a safe dose and check for side effects. Up to 36 participants wil…

This trial tests an experimental drug called CS5001, designed to seek out and destroy cancer cells that carry a specific marker (ROR1). It is being studied in people with advanced solid tumors or lymphomas that have progressed after standard treatments. The study will first find …

This early-stage trial tests two experimental pills (PF-07799544 and PF-07799933) taken twice daily at home by adults with advanced solid tumors that have a specific gene change called BRAF V600. The study aims to find safe doses and see if the drugs can shrink tumors. About 124 …

This study tests a new drug, DS-1062a, in people with advanced solid tumors like lung and breast cancer that haven't responded to other treatments. It's the first time this drug is being used in humans, so the main goals are to check safety, find the right dose, and see if it hel…

This study tests two immunotherapy drugs, durvalumab and tremelimumab, with or without chemotherapy, in 301 people with stage IV non-small cell lung cancer. The goal is to see if these drugs help patients live longer by helping their immune system fight the cancer. Participants m…

This phase 3 study tests whether adding the targeted drug amivantamab to standard chemotherapy helps people with advanced non-small cell lung cancer that has a specific EGFR mutation (exon 20 insertion). About 308 participants will receive either the combination or chemotherapy a…

This study tests a new drug called Dato-DXd in Chinese patients with advanced non-small-cell lung cancer or triple-negative breast cancer that has spread or stopped responding to treatment. The drug targets and kills cancer cells by attaching to them and blocking growth. About 11…

This phase 2 trial is testing a combination of two immunotherapy drugs, zimberelimab and domvanalimab, as a first treatment for people with advanced non-small cell lung cancer that has high levels of a protein called PD-L1. The study includes 169 participants and aims to see if t…

This study tests whether early, personalized nutritional support and a simple home exercise program can prevent weight loss and improve quality of life in 200 adults with lung, colorectal, ovarian, or pancreatic cancer starting palliative chemotherapy. Participants receive guidan…

This early-phase trial is testing whether adding two drugs, dupilumab and anakinra, to standard immunotherapy can help people with advanced non-small cell lung cancer whose cancer has stopped responding to treatment. About 33 participants will receive the combination to see if it…

This early-phase trial is testing an experimental drug called AB598, alone or with other cancer drugs, in 40 people with advanced solid tumors like lung, bladder, or breast cancer. The main goal is to check safety and find the right dose. It is not yet known if the drug helps shr…

This study tests a drug called MRG003 in adults whose nasopharyngeal cancer has come back or spread and hasn't responded to standard treatments. The goal is to see if the drug can shrink tumors and how safe it is. About 238 participants will receive the drug, and researchers will…

This study tests a new drug called Cetrelimab (JNJ-63723283) in 234 people with advanced solid tumors like lung, melanoma, bladder, and colorectal cancers. The drug works by blocking PD-1, a protein that stops the immune system from attacking cancer cells. The trial has two parts…

This study tests a new drug called volrustomig combined with other cancer treatments for people with advanced non-small cell lung cancer. The main goals are to check safety and see if tumors shrink. About 180 adults will take part in this early-stage trial.

This study tests a new form of the drug amivantamab that can be given as a shot under the skin, combined with the pill lazertinib, for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer) that has worsened after prior treatments. The goal …

This study tests whether giving the targeted drug osimertinib before and after standard chemoradiation helps control stage III lung cancer that cannot be removed by surgery. About 76 adults with a specific EGFR gene mutation will receive the drug as induction therapy, then contin…

This study tests an experimental drug called CTL-002, given alone or with an approved immunotherapy, in people with advanced solid tumors that have stopped responding to standard treatments. The goal is to find a safe dose and see if the combination can shrink tumors or slow thei…

This study tests an experimental drug called AZD5305, a PARP inhibitor, either alone or combined with other cancer drugs in people with advanced solid tumors (like ovarian, breast, pancreatic, and lung cancers). The goal is to see if the treatment is safe and can shrink tumors. A…

This phase 3 trial tests whether adding the drug Dato-DXd to standard immunotherapy (pembrolizumab) helps people with advanced or metastatic non-small cell lung cancer live longer without their cancer growing. About 740 adults with a high level of a protein called PD-L1 will be r…

This study tests a drug called trastuzumab deruxtecan (T-DXd) in 72 people with a specific type of advanced lung cancer (HER2-mutant non-small cell lung cancer) that has worsened after at least one prior treatment. The goal is to see if the drug can shrink tumors and how safe it …

This phase II trial tests a combination of immunotherapy (durvalumab), chemotherapy (carboplatin and paclitaxel), and targeted radiation to metastatic spots, followed by surgery or radiation to the main lung tumor. The goal is to see if this aggressive approach can keep the cance…

This phase 3 trial is testing whether adding the immunotherapy drug toripalimab to standard chemotherapy and radiation can improve outcomes for people with locally advanced nasopharyngeal carcinoma, a type of head-and-neck cancer. Participants will receive either toripalimab or a…

This study tests a new drug called gotistobart (ONC-392) against standard chemotherapy (docetaxel) in people with advanced non-small cell lung cancer that worsened after prior immunotherapy. About 630 adults will receive either the new drug or chemotherapy every 3 weeks for up to…

This phase 2 study tests two targeted drugs, encorafenib and binimetinib, in 119 people with advanced non-small cell lung cancer that has a specific BRAF V600E mutation. The goal is to see if the combination can shrink tumors and keep them from growing. Participants take the pill…

This phase 2 trial is testing whether a chemotherapy combination without etoposide (carboplatin plus paclitaxel) plus the immunotherapy drug durvalumab works better than standard treatment for people with extensive-stage small cell lung cancer. About 67 participants will receive …

This phase 3 trial is comparing an experimental targeted drug called adagrasib (MRTX849) with the standard chemotherapy docetaxel in people with advanced non-small cell lung cancer that has a specific KRAS G12C mutation and has already been treated. The study aims to see if adagr…

This phase 2 study tests an oral drug called selpercatinib in 77 people in China who have advanced solid tumors or medullary thyroid cancer with specific RET gene changes. The goal is to see if the drug can shrink tumors and how safe it is. Participants take the pill daily, and d…

This phase 3 trial tests whether the immunotherapy drug durvalumab can help people with stage III non-small cell lung cancer that hasn't grown after chemoradiation. About 400 participants receive either durvalumab or a placebo every 4 weeks. The goal is to see if durvalumab delay…

This study tests whether adding savolitinib to osimertinib works better than chemotherapy for people with a certain type of advanced lung cancer (EGFR-mutated, MET-positive) that has stopped responding to osimertinib. About 345 adults will be randomly assigned to receive either t…

This early-stage trial is testing an experimental oral drug, TYRA-200, in people with advanced bile duct cancer (intrahepatic cholangiocarcinoma) and other solid tumors that have specific changes in the FGFR2 gene. The study aims to find a safe and effective dose and to see wheth…

This early-phase trial tests whether adding Tumor Treating Fields (TTFields) — a device that delivers electric fields to the tumor — to standard chemoradiation and immunotherapy is safe for people with stage III non-small cell lung cancer that cannot be removed by surgery. About …

This study tests whether taking osimertinib for 5 years after surgery can prevent lung cancer from coming back in people with a specific EGFR mutation. About 188 adults with stage II-IIIB non-small cell lung cancer who had their tumor fully removed will take the drug. The main go…

This study tests whether adding high-dose vitamin C (ascorbate) to the usual treatment of radiation and chemotherapy can help control non-small cell lung cancer. About 43 participants will receive the vitamin C alongside their standard therapy. The goal is to see if the combinati…

This study tests a combination of three drugs (chemotherapy, anti-angiogenesis, and immunotherapy) in 30 adults with advanced non-small cell lung cancer that worsened after standard treatments. The goal is to see if this triple therapy is safe and works better than current option…

This trial tests whether analyzing a child's DNA before prescribing supportive care drugs can lower the risk of serious side effects. Children with cancer or those receiving a bone marrow transplant are randomly assigned to get either standard care or prescribing guided by their …

This trial investigates whether real-time motion management techniques—like triggered imaging and MLC tracking—can safely reduce the target margins used during radiotherapy for prostate and lung cancer. By adjusting the radiation beam to follow tumor movement, researchers aim to …

This phase 2 trial tests whether adding plinabulin to a standard combination of pembrolizumab and docetaxel can shrink tumors or slow disease progression in people with metastatic non-small cell lung cancer that has worsened after prior immunotherapy. About 47 adults with advance…

This phase 2b trial tests whether the immunotherapy drug tremelimumab can help people with advanced mesothelioma live longer. About 571 patients who have already tried standard chemotherapy will receive either tremelimumab or a placebo. The main goal is to see if the drug improve…

This trial tests whether precisely targeted radiation (SABR) to a small number of growing tumors, while continuing current drug therapy, can delay overall disease progression in people with metastatic non-small cell lung cancer. About 68 participants whose cancer has started to g…

This phase 2 study tests a drug called tarlatamab in 222 people with relapsed or refractory small cell lung cancer who have already tried at least two prior treatments. The goal is to see if tarlatamab can shrink tumors and how safe it is. Participants receive the drug through an…

This phase 3 trial tests whether adding selumetinib (a targeted therapy) to standard chemotherapy (docetaxel) helps people with advanced KRAS-mutant lung cancer live longer without their cancer growing. About 510 adults whose cancer worsened after first treatment will receive eit…

This phase 3 trial tests whether adding the immunotherapy drug durvalumab to standard radiation therapy helps prevent early-stage non-small cell lung cancer from progressing. It includes about 724 patients who cannot have surgery. A separate group of patients with a specific EGFR…

This trial is for people with advanced cancers who have already responded well to 6 months of standard immunotherapy. It compares continuing the same drugs at the usual frequency versus giving them every 3 months. The goal is to see if the reduced schedule can prevent cancer prog…

This study tested adding the immunotherapy drug durvalumab (with or without another drug, tremelimumab) to standard chemotherapy for people with extensive-stage small-cell lung cancer, a fast-growing cancer that has spread. About 987 participants received either chemo alone or ch…

This study is testing a combination of three drugs—durvalumab (an immunotherapy), olaparib (a targeted therapy), and bevacizumab (a drug that blocks blood vessel growth)—in people with advanced solid tumors, including ovarian, breast, lung, and gastric cancers. The goal is to see…

This trial tests whether removing the lung tumor before the lymph nodes, or the lymph nodes before the tumor, leads to better long-term survival in people with early-stage non-small cell lung cancer. About 620 patients will be randomly assigned to one of the two sequences. The st…

This study tests a drug called sacituzumab govitecan (Trodelvy) in Japanese patients with advanced solid tumors, including certain breast and bladder cancers. The trial has two phases: first, to find the safest dose, and second, to see how well the drug shrinks tumors. Participan…

This early-phase trial tests an experimental immunotherapy called ELI-002 7P in people with pancreatic or other solid tumors that have specific KRAS or NRAS gene mutations. The treatment aims to train the immune system to attack cancer cells. About 158 participants will receive t…

This Phase 2 trial tests the targeted drug lazertinib, alone or with chemotherapy, before surgery in 160 adults with EGFR-mutant non-small cell lung cancer (stages IB to IIIB). The goal is to see if these treatments can shrink tumors enough to improve surgical outcomes. Participa…

This phase 2 trial tests a combination of three drugs—daratumumab, a KRAS vaccine, and nivolumab—in people with advanced pancreatic cancer or non-small cell lung cancer that has not responded to prior treatment. The goal is to see if the combination can shrink tumors or slow canc…

This study tests a virus called AdAPT-001 that is injected directly into tumors to kill cancer cells. It is for adults with advanced solid tumors that have not responded to standard treatments. The trial will check if the virus is safe and whether it works better when combined wi…

This early-phase trial tests whether adding the experimental drug binimetinib to the immunotherapy pembrolizumab (Keytruda) helps people with advanced non-small cell lung cancer. The study includes 40 participants whose tumors have high PD-L1 levels. Researchers are looking at sa…

This early-phase trial tests a new drug, ASTX660, combined with the immunotherapy pembrolizumab in people with advanced solid tumors, including cervical and triple-negative breast cancers. The goal is to see if the combination is safe and can boost the immune system to fight canc…

This phase 2 trial tests whether continuing the immunotherapy drug cemiplimab for up to a year after initial treatment can delay cancer growth in people with stage IV non-small cell lung cancer that has spread to only a few places (oligometastatic). About 136 participants will be…

This phase 2 trial tests the experimental drug MGC018 in 9 people with relapsed or refractory extensive-stage small-cell lung cancer. The main goal is to see if the drug can shrink tumors in at least 25% of patients. Participants receive MGC018 by IV every 28 days until the cance…

This early-phase trial tests an experimental drug called IPH5301, which targets a protein called CD73 on cancer cells. The study involves 27 people with advanced solid tumors, including breast, lung, and pancreatic cancers. In the first part, IPH5301 is given alone to find a safe…

This Phase III trial tests whether adding oleclumab or monalizumab to the standard drug durvalumab can help people with stage III non-small cell lung cancer that hasn't worsened after chemoradiation. About 1,050 participants will receive one of the combinations or a placebo. The …

This study tests an experimental drug called CLN-081 in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). Participants must have already received chemotherapy. The goal is to see if the drug is safe and can shrink tumors.

This study follows 254 adults with extensive-stage small cell lung cancer who are receiving durvalumab (Imfinzi) along with standard chemotherapy. The goal is to see how long patients stay on treatment and how well it works in real-world settings. The approach uses the immune sys…

This phase 2 trial is testing whether combining pembrolizumab (an immunotherapy) with olaparib (a PARP inhibitor) can shrink tumors in people with nasopharyngeal cancer that has become resistant to platinum-based chemotherapy. The study plans to enroll 30 adults whose cancer has …

This study looks at how well a combination of two immunotherapy drugs (nivolumab and ipilimumab), with or without chemotherapy, works as a first treatment for advanced or recurrent non-small cell lung cancer in Japan. Researchers will track about 525 patients to measure survival,…

This study tests whether using a sensitive blood test (MRD) to guide follow-up treatment can improve outcomes for people with a specific type of advanced lung cancer (EGFR-mutant stage III NSCLC). Participants first receive a targeted pill (aumolertinib), then a team of doctors d…

This study tests a drug called 177Lu-DOTATATE, which delivers radiation directly to cancer cells, in people with metastatic nasopharyngeal cancer that has not responded to at least two prior treatments. Only patients whose tumors show up on a special scan are eligible. The main g…

This study tests a new drug called PLB1004 in people with advanced or spreading non-small cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). The goal is to see if the drug can shrink tumors and how safe it is. About 139 adults who have already tried oth…

This early-phase trial tests a combination of three drugs—tarlatamab, YL201, and durvalumab—in 29 adults with extensive stage small cell lung cancer that has progressed after prior treatment. The main goal is to check safety and side effects, while also measuring how well the tum…

This early-phase trial is testing whether adding the immunotherapy drug ipilimumab (Yervoy) to the targeted therapy osimertinib (Tagrisso) is safe and tolerable for people with a specific type of advanced lung cancer (EGFR-mutated non-small cell lung cancer). The study involves 2…

This early-stage trial tests a new drug called EM-I-2024, made from a modified enterovirus, in 24 adults with advanced solid tumors that cannot be surgically removed and have not responded to other treatments. The drug is given either intravenously or directly into the artery fee…

This phase 2 trial tests two drugs, durvalumab and oleclumab, given together after standard chemoradiation in 30 people with stage III lung cancer that cannot be removed by surgery. The goal is to see if the combination can delay cancer progression. Participants must have stable …

This early-phase study tests a combination of two drugs—guadecitabine and pembrolizumab—in about 60 people with advanced solid tumours (like lung cancer) that no longer respond to standard therapies. The main goal is to find the safest dose and check for side effects. Researchers…

This early-phase trial tests two oral cancer drugs, niraparib and neratinib, given together. The first part aims to find the safest dose in people with advanced solid tumors. The second part checks if that dose can keep platinum-resistant ovarian cancer from growing for at least …

This early-phase study tests a new type of immune cell therapy (universal CAR-T) in 60 adults with advanced liver or lung cancer that has not responded to standard treatments. The main goals are to find a safe dose and check for side effects, while also measuring how well the the…

This phase 3 trial compares a new targeted drug, sacituzumab govitecan, against the standard chemotherapy docetaxel in 603 people with advanced non-small cell lung cancer that has worsened after prior treatments. The main goal is to see if the new drug helps people live longer. T…

This phase 2 trial is testing whether combining two drugs, ensartinib and bevacizumab, can help people with advanced lung cancer that has both an ALK rearrangement and a TP53 mutation. The study includes 47 participants who take ensartinib daily and receive bevacizumab every thre…

This Phase III trial tests whether adding immunotherapy to standard chemotherapy after lung cancer surgery can delay or prevent the cancer from coming back. It enrolls 210 patients with stage IB-IIIA non-small cell lung cancer that was completely removed. Participants are randoml…

This phase 2 trial tests giving chemotherapy (carboplatin and paclitaxel) plus the immunotherapy drug nivolumab before surgery for people with Pancoast tumors, a rare type of lung cancer. After surgery, additional treatment is tailored based on whether the tumor was fully removed…

This phase II trial tests whether adding stereotactic ablative radiotherapy (SABR) to standard anti-cancer therapy improves survival for people with non-small cell lung cancer that has spread to only a few spots (oligometastatic). About 140 participants are randomly assigned to r…

This phase 2 trial is testing a combination of two immunotherapy drugs (nivolumab and ipilimumab) plus two cycles of chemotherapy as a first treatment for people with advanced lung cancer that has spread to the brain. The study aims to see if this approach can control the cancer …

This early-phase study tests a radioactive drug (177Lu-PP-F11N) that seeks out and attaches to cancer cells in people with advanced medullary thyroid cancer and certain other neuroendocrine tumors. The goal is to see if the drug can help image tumors and deliver targeted radiatio…

This phase 2 study tests a combination of two targeted drugs, encorafenib and binimetinib, in Chinese patients with advanced non-small cell lung cancer that has a specific BRAF V600E mutation. The goal is to see if the drugs can shrink tumors and control the disease. About 63 pat…

This phase II trial tests whether adding immunotherapy to standard chemotherapy before surgery helps eliminate more lung cancer in patients with advanced, but potentially removable, non-small cell lung cancer. 90 participants will be randomly assigned to receive either chemo-immu…

This phase II trial is testing whether adding two targeted drugs (pembrolizumab and lenvatinib) to standard chemotherapy can help people with extensive-stage small cell lung cancer live longer without their cancer growing. The study involves 46 participants who have not had prior…

This study tests a two-step treatment for people with a specific type of lung cancer (EGFR-mutant, stage II-IIIB). First, patients take a targeted pill (almonertinib), then receive a combination of immunotherapy (adebrelimab) and chemotherapy. After these treatments, they have su…

This study tests whether adding an experimental drug called NP137 to standard immunotherapy (PD-1/PD-L1 blockers) can help shrink or control advanced solid tumors that are stable or resistant to treatment alone. About 57 adults with various advanced cancers will receive the combi…

This early-phase trial tests two drugs, tepotinib and pembrolizumab, together in 19 people with advanced non-small cell lung cancer. Tepotinib targets a specific gene change (MET) that can help cancer grow, while pembrolizumab boosts the immune system. The goal is to see if this …

This Phase 3 study is testing whether a combination of three drugs—datopotamab deruxtecan (Dato-DXd), durvalumab, and carboplatin—works better than the current standard treatment (pembrolizumab plus chemotherapy) for people with advanced non-small cell lung cancer that does not h…

This study tests a new drug called PLB1004 against standard chemotherapy for people with advanced non-small-cell lung cancer that has a specific genetic change (EGFR exon 20 insertion). About 327 adults with this cancer type will be randomly assigned to receive either PLB1004 or …

This phase 2 study tests whether adding savolitinib to osimertinib can shrink tumors in people with advanced non-small cell lung cancer that has a specific genetic change (EGFR mutation) and has stopped responding to osimertinib alone. About 367 participants will receive the drug…

This early-phase trial tests a personalized vaccine (PANDA-VAC) made from a patient's own tumor markers, given alongside the immunotherapy drug pembrolizumab. It includes up to 6 people with advanced squamous cell lung cancer or head and neck cancer that cannot be cured. The main…

This study tests a combination of three drugs—bevacizumab, nab-paclitaxel, and a platinum drug—as a second-line treatment for people with advanced non-squamous non-small cell lung cancer that does not have certain genetic mutations. The cancer must have worsened after first-line …

This phase II trial tests whether the immune-boosting drug durvalumab can help frail patients with limited-stage small cell lung cancer keep their disease from progressing after standard chemoradiotherapy. About 100 participants who have stable or improved disease after initial t…

This study tests an oral drug called selpercatinib in people with advanced solid tumors that have RET gene alterations, including certain lung, thyroid, and colon cancers. The goal is to find the best dose and see if the drug can shrink tumors. About 857 participants are enrolled…

This phase II trial is testing whether adding the immunotherapy drug atezolizumab to standard chemotherapy (platinum and etoposide) can help people with advanced large-cell neuroendocrine lung cancer live longer. About 67 participants who have not had prior systemic treatment wil…

This study tests whether adding the immunotherapy drug atezolizumab after standard chemo-radiotherapy helps people with limited-stage small-cell lung cancer live longer. About 212 participants will receive either atezolizumab or no additional treatment after chemo-radiation. The …

This study tests whether using a special breathing device (AEROBIKA) after chest surgery can help prevent lung collapse (atelectasis) in people with lung cancer, mediastinal tumors, or mesothelioma. About 72 participants will be randomly assigned to either standard rehab therapy …

This phase 1 trial tests a special type of radiation therapy for lung tumors located very close to the windpipe or esophagus. Using real-time MRI guidance, doctors can adapt the radiation dose daily to target the tumor while sparing nearby organs. Up to 38 patients will receive o…

This study was designed to test two immunotherapy drugs, atezolizumab and tiragolumab, in people with advanced lung cancer that has special immune cell clusters called tertiary lymphoid structures. The trial was withdrawn before enrolling any participants, so no results are avail…

This study tests a new treatment for cancers linked to the Epstein-Barr virus (EBV), such as Hodgkin lymphoma and nasopharyngeal carcinoma. The treatment uses immune cells from healthy donors that are specially trained to attack EBV-infected cells. These cells are stored in a ban…

This study tests a new drug called JDQ443, alone or with other treatments, for people with advanced solid tumors that have a specific genetic change called KRAS G12C. The goal is to find the safest dose and see if the drug can shrink tumors. About 344 adults whose cancer has not …

This study tested whether adding the immunotherapy drugs durvalumab (with or without tremelimumab) to standard chemotherapy helps people with advanced non-small cell lung cancer live longer or keep their cancer from growing. About 1,186 adults with metastatic NSCLC who had not re…

This phase 2 trial tests whether a combination of two immunotherapy drugs (ipilimumab and cemiplimab) plus targeted radiation can help people with advanced non-small cell lung cancer whose previous immunotherapy stopped working. The study enrolls 54 participants and aims to see i…

This study tests two different chemotherapy plus immunotherapy combinations in people with advanced lung cancer that has a specific marker (TTF-1 negative). About 136 participants will be randomly assigned to one of two treatment groups. The goal is to see which combination helps…

This Phase I trial tests a combination of two oral drugs, defactinib and VS-6766, in people with advanced solid tumors such as non-small cell lung cancer, low-grade serous ovarian cancer, and pancreatic cancer. The study aims to find the safest dose and evaluate how well the drug…

This early-stage trial is for people with stage IV non-small cell lung cancer. It tests whether giving targeted radiation before or at the same time as two immunotherapy drugs (nivolumab and ipilimumab) is safe. The goal is to find the best radiation dose for different tumor loca…

This study tests a text-message chatbot called 'Penny' that sends reminders and checks in on symptoms for lung cancer patients taking daily targeted therapy pills. 75 patients will either use the chatbot or get usual care, and researchers will measure how well they stick to their…

This study is testing a new approach for people with malignant pleural mesothelioma, a rare lung cancer. It combines high-dose radiation (including a special boost to target bulky tumors) with surgery to remove the affected tissue. The main goal is to find the highest safe radiat…

This phase 2 trial tests whether adding the immunotherapy drug toripalimab to standard chemotherapy and radiation can help people with large, locally advanced non-small cell lung cancer. About 50 participants will receive two cycles of toripalimab plus chemo, followed by chemorad…

This early-stage trial is testing whether a combination of two drugs, naporafenib and trametinib, can shrink or control advanced solid tumors that have a specific genetic change called RAS Q61X. About 86 people whose cancer has not responded to standard treatments will receive th…

This Phase 3 trial tests whether adding radiation to the standard combination of pembrolizumab (an immunotherapy) and chemotherapy can improve survival in people with advanced non-small cell lung cancer. About 327 participants with stage IIIB/IV disease will receive either the tr…

This early-phase trial planned to test a new approach for people with metastatic non-small cell lung cancer. Doctors would remove immune cells from the tumor, edit them with CRISPR to remove a gene called CISH, and then infuse them back to help fight the cancer. However, the tria…

This study tests a new way for cancer doctors and primary care doctors to work together to help cancer survivors manage other health problems like high blood pressure, diabetes, and high cholesterol. About 800 adults with certain cancers and at least one of these conditions will …

This early-phase trial tests an experimental drug called IMP321, which activates immune cells, in combination with other cancer treatments like chemotherapy or immunotherapy. The study includes 83 people with advanced solid tumors, including lung and bladder cancers. The main goa…

This Phase 2 trial tests a genetically modified herpes virus (RP1) alone or with the immunotherapy drug nivolumab in people with advanced solid tumors, including melanoma, non-small cell lung cancer, and certain skin cancers. The study aims to see if the combination is safe and c…

This early-stage trial is testing a new cell therapy called GK01 combined with a PD-1 immune checkpoint inhibitor in 15 people with advanced solid tumors (such as lung, stomach, or colorectal cancer). The main goal is to see if the combination is safe and tolerable, while also ch…

This phase 2 trial tests the drug T-DXd (Enhertu) in 27 adults with advanced HER2-mutant lung cancer that has spread to the brain but is not causing symptoms. The main goal is to see how long the drug can keep brain tumors from growing. T-DXd is already approved for certain lung …

This Phase 2 trial compares the drug atezolizumab alone versus atezolizumab plus bevacizumab as a first treatment for people with advanced non-small-cell lung cancer that has a specific marker (PD-L1). About 206 patients are taking part. The main goal is to see if the combination…

This phase 3 study tests whether the targeted drug abemaciclib can help people with stage IV lung cancer that has a KRAS mutation and has worsened after chemotherapy. About 450 participants received either abemaciclib or another targeted drug (erlotinib), both alongside best supp…

This study tests two drug combinations (Tedopi plus docetaxel or Tedopi plus nivolumab) in people with advanced non-small-cell lung cancer whose disease worsened after initial chemo-immunotherapy. About 105 participants with a specific genetic marker (HLA-A2+) will receive one of…

This study looks at whether a blood test (liquid biopsy) can help doctors see how well the drug brigatinib is working in people with a certain type of advanced lung cancer (ALK-positive NSCLC). About 33 patients who have not had chemotherapy before will take brigatinib pills dail…

This study tests a new device that uses microwave energy to destroy small lung tumors. The device is inserted through a bronchoscope, avoiding the need for open surgery. The trial will enroll 35 people with lung nodules that are cancerous or highly suspicious, and who cannot have…

This phase 2 trial tests a combination of lazertinib (a targeted pill) plus two chemotherapy drugs (pemetrexed and carboplatin) in 87 adults with a specific type of advanced lung cancer (EGFR mutation-positive non-small cell lung cancer) that has stopped responding to lazertinib …

This phase II trial is testing a combination of three drugs—anlotinib, penpulimab, and capecitabine—as a first treatment for people whose nasopharyngeal cancer has come back or spread. The study includes 59 adults aged 18 to 65 who have not had prior systemic therapy for their re…

This phase II trial tests whether adding two drugs (amivantamab and bevacizumab) to the targeted therapy lazertinib can shrink tumors in 60 people with advanced EGFR-mutant non-small cell lung cancer whose disease progressed on a prior targeted therapy. The main goal is to see ho…

This Phase 3 trial tests whether adding ramucirumab (a drug that blocks blood vessel growth) to the standard targeted therapy erlotinib can help people with a specific type of advanced lung cancer (EGFR-mutated NSCLC) live longer without their cancer getting worse. About 545 peop…

This phase 2 trial is testing whether it is safe and effective to continue the targeted therapy osimertinib while also giving radiation to areas where lung cancer has started to grow again. The study includes 42 adults with EGFR-positive non-small cell lung cancer who are already…

This trial tests a new drug called roginolisib combined with two other drugs (dostarlimab and docetaxel) in 45 adults with advanced non-squamous lung cancer that has worsened after standard treatments. The main goals are to see if the combo is safe and whether it reduces certain …

This study tests a new way to give radiation therapy to people with malignant pleural mesothelioma, a rare and serious lung cancer. The treatment uses a special machine called Tomotherapy to deliver high doses of radiation over just 5 days. The goal is to see if this short, inten…

This study tests a new drug called TYRA300 in people with advanced bladder cancer or other solid tumors that have a specific change in the FGFR3 gene. The goal is to find the best dose and see if the drug can shrink tumors. About 310 adults whose cancer has not responded to stand…

This study tests whether giving a combination of the immunotherapy drug pembrolizumab and chemotherapy before surgery can help people with a rare cancer called pleural mesothelioma. The trial involves 41 adults with early-stage disease that can be surgically removed. The main goa…

This early-phase trial tests a new approach to treat advanced solid tumors by giving patients a large dose of their own immune cells that are specially selected to attack cancer. The cells are taken from the tumor, multiplied in the lab, and then infused back. Some patients also …

This study tests an oral drug called selpercatinib (LOXO-292) in children with advanced solid or brain tumors that have a specific RET gene change. The trial has two parts: first finding a safe dose, then measuring how many children's tumors shrink. About 36 children whose cancer…

This phase 3 study compares tarlatamab, an experimental drug, to standard treatments in about 500 adults with small cell lung cancer that returned after initial chemotherapy. The main goal is to see if tarlatamab helps people live longer. Participants must have measurable disease…

This program provides taletrectinib, a targeted cancer pill, to adults with advanced or metastatic ROS1-positive non-small cell lung cancer who cannot join a clinical trial or use approved treatments. Patients must have a ROS1 gene fusion and adequate organ function. The goal is …

This study tests whether adding a light-activated drug (photodynamic therapy) during surgery can help people with a rare lung cancer called epithelioid malignant pleural mesothelioma live longer. About 52 adults with cancer limited to one side of the chest will receive either sta…

This early-phase trial tests a personalized vaccine called Microlyvaq™ for people with advanced non-small cell lung cancer. The vaccine is custom-made for each patient using AI and quantum modeling to target their unique tumor mutations. It is given alongside standard chemotherap…

This phase 2 trial tests whether adding a PD-1 inhibitor (a type of immunotherapy) to standard chemotherapy before radiation can improve outcomes for people with advanced nasopharyngeal carcinoma. About 150 participants will receive either the combination or chemotherapy alone, f…

This early-stage study tests a new treatment called BOXR1030 for people with advanced solid tumors that have a specific marker (GPC3). The treatment uses specially designed immune cells given after chemotherapy to help fight the cancer. The main goals are to check safety and find…

This study looks at whether adding a high-precision type of radiation called SBRT to usual cancer treatments (like hormone therapy or chemo) can delay cancer growth in people with breast, lung, or prostate cancer that has spread to 1 to 5 bones. About 168 adults aged 18-75 with g…

This study tests a new drug called DS-1062a in 100 people with advanced non-small cell lung cancer that has worsened after standard treatments. The drug is given every three weeks and aims to shrink tumors. Researchers will also study how the drug affects the immune system and lo…

This phase 3 trial tests whether the immunotherapy drugs durvalumab (with or without tremelimumab) can help prevent cancer progression in people with limited-stage small cell lung cancer who have completed chemoradiation. About 730 participants will receive either the drug combin…

This phase 2 study tests whether adding chemotherapy to the targeted drug brigatinib helps people with advanced ALK-positive non-small cell lung cancer live longer without their cancer growing. About 110 people who have not had treatment for advanced disease will receive either b…

This study looks at whether adding the immunotherapy drug atezolizumab to standard chemotherapy helps elderly patients (70+) with advanced non-small cell lung cancer live longer. About 510 participants will receive either chemotherapy alone or chemotherapy plus atezolizumab. The …

This study tests whether adding an immunotherapy drug (atezolizumab) to a standard two-drug chemotherapy (paclitaxel and bevacizumab) can help people with advanced non-squamous lung cancer whose disease has worsened after prior immunotherapy and chemotherapy. About 156 participan…

This early-stage trial tests a new drug called TPX-0022 in adults with advanced lung, stomach, or other solid tumors that have specific MET gene changes. The main goals are to check the drug's safety, find the best dose, and see if it shrinks tumors. About 95 participants will ta…

This study planned to test a targeted cancer pill (adagrasib) alone or with an immunotherapy drug (nivolumab) before surgery in people with a specific type of lung cancer (KRAS G12C mutation). The goal was to see if these drugs could eliminate all cancer cells by the time of surg…

This Phase 3 trial tests whether giving a three-drug chemotherapy regimen (docetaxel, cisplatin, and fluorouracil) before radiotherapy helps people with advanced laryngeal or hypopharyngeal cancer avoid losing their voice box. The standard approach is to give cisplatin during rad…

This early-stage trial tests a radioactive imaging agent called RAD301 in 9 people: healthy volunteers and patients with pancreatic, lung, esophageal, cervical, endometrial, or ovarian cancer. The goal is to see how safe it is and how it travels through the body. If it works, it …

This expanded access program lets people with advanced solid tumors receive an investigational imaging agent called MNPR-101-DFO*-89Zr before a PET/CT scan. The agent is designed to bind to uPAR, a protein found at higher levels in some tumors than in normal tissue. The goal is t…

Researchers are testing an experimental imaging agent called MNPR-101-DFO*-89Zr in people with several types of solid tumors, including bladder, breast, lung, and pancreatic cancers. The agent combines an antibody with a radioactive label, which may help PET scans reveal where tu…

Researchers are testing whether a blood test that looks at DNA methylation patterns can find nasopharyngeal carcinoma earlier and more accurately than the standard Epstein-Barr virus (EBV) tests. The study will compare the new multi-omics model with EBV DNA quantification and two…

This trial tests whether a blood test that detects circulating tumor DNA (ctDNA) can predict when advanced non-small cell lung cancer might progress in people who have already benefited from first-line immunotherapy for at least 12 months. Researchers will follow 100 participants…

This study tests a new PET imaging tracer called [18F]F-AraG to see if it can spot activated T-cells inside non-small cell lung cancer tumors. Researchers will scan about 10 patients with resectable lung cancer, then compare the tracer's uptake with lab analysis of the removed tu…

This trial tests whether artificial intelligence can detect anxiety and depression in cancer patients by analyzing their facial expressions and subtle skin color changes from video. The AI uses computer vision to estimate heart rate and read emotional cues, aiming to flag patient…

This trial tests whether an experimental imaging agent, 18F-LNC1007, can improve the detection, staging, and recurrence monitoring of tumors compared to the standard 18F-FDG PET/CT scan. Adults with suspected or confirmed tumors will receive both types of scans within a week, and…

This trial tests whether an AI tool called ENLIGHT can help pathologists more accurately and quickly distinguish between certain lung and kidney cancer subtypes. Pathologists will review digitized slides under three conditions: without AI, with AI as a double-check after their ow…

This study aims to improve early detection of lung cancer in Asian women who have never smoked, a group at higher risk but not covered by standard screening guidelines. Participants receive up to three low-dose CT scans and a blood test designed to spot early signs of cancer. Res…

This study compares a robotic bronchoscopy system (Ion) to a manual one (superDimension) for diagnosing lung nodules. About 354 adults with suspicious lung nodules will be randomly assigned to one of the two devices. The main goal is to see which device yields a correct diagnosis…

This study collects blood samples from 872 people with lung nodules to develop artificial intelligence (AI) tools that can help diagnose lung cancer earlier and more accurately. The goal is to combine blood tests with CT scans to improve detection and reduce the need for invasive…

This study tests a new type of CT scan, called Photon-Counting CT, to see if it can more accurately show how far laryngeal cancer has spread. Sixty adults with laryngeal cancer will get this scan while making a sound, which may help separate normal tissues from tumor. The goal is…

This Italian study is testing whether heavy smokers can be screened for lung cancer just as effectively with a CT scan every two years instead of every year, and whether a simple blood test can help catch cancers early. Over 7,300 current or former heavy smokers are taking part a…

This study is testing a new blood test (called DELFI) to see how well it can find lung cancer in people at high risk, such as current or former smokers aged 50 and older. Over 11,000 participants provided blood samples, and the test results were compared with standard CT scans an…

This study compares a new AI system, called COSMO, against 30 board-certified pathologists to see who can more accurately diagnose brain, lung, and kidney cancers. Both the AI and the pathologists will review the same 300 de-identified tissue images. The goal is to see if AI can …

This study looks at a new lab technique called OSNA that may find tiny amounts of cancer in lymph nodes better than current methods. About 130 people with early-stage lung cancer having robotic surgery will take part. Half will have their lymph nodes checked with OSNA, the other …

This study tests whether a liquid biopsy (a blood test that looks for cancer DNA) can help doctors decide on treatment for advanced lung cancer faster than the usual method of testing tumor tissue. About 170 newly diagnosed patients will receive both the blood test and standard t…

Researchers are testing whether a 14-gene test can identify people with early-stage non-squamous non-small cell lung cancer who are at higher risk of the cancer returning after surgery. Patients whose tumors are completely removed and who test as intermediate or high risk are ran…

This study tests whether mobile lung cancer screening units can increase participation among rural adults aged 50 to 80 who smoke or quit within the last 15 years. Researchers will measure how many people get screened and whether their knowledge about lung cancer changes. The goa…

This study tests whether a combination of low-dose aspirin, a smoking cessation drug called cytisine, and guidance on diet and exercise can reduce chronic inflammation and lower lung cancer risk in heavy smokers aged 55 to 75. The 2000 participants will also receive annual low-do…

This study is testing a culturally adapted mindfulness program for Latino cancer patients and their family caregivers. The goal is to see if the program is practical and helpful for reducing stress and anxiety. About 68 patient-caregiver pairs will take part, with some starting t…

This study tests a 6-week mindfulness-based program for lung cancer patients struggling with breathlessness, cough, and fatigue. The program combines mindful breathing, relaxation, cough control, acupressure, and light exercise. Researchers will check if it's practical and liked …

This study tests a supportive care program designed specifically for Black patients with advanced cancer. Participants will join weekly online sessions for four weeks, either practicing meditation or learning coping skills. The goal is to see if this culturally adapted program is…

This study tests a new tool called the Buckeye Quit Stick to help smokers with lung cancer quit. The stick replaces the hand-to-mouth habit of smoking without using medicine. About 30 adults will try it for 6 months to see if it helps them stay smoke-free.

Researchers are testing a virtual stress-management program for people who care for a spouse or partner with a solid tumor cancer while also holding a job. The program teaches skills such as paced respiration, relaxation, and coping with work and caregiving demands across eight s…

This study tests a program called CostCOM that helps cancer patients with the high costs of treatment. Many patients skip or delay care because of money worries. The program provides financial advice and connects patients to resources. Researchers want to see if it helps patients…

This study tests a new web-based tool called CONNECT, designed to help caregivers of people with stage II to IV lung cancer find support resources. About 216 caregivers will use the tool and have sessions with a navigator to see if it helps them feel more supported. The goal is t…

This study tests a telemedicine program called FOCUS that helps advanced cancer patients manage common symptoms like trouble sleeping, worry, tiredness, and low mood. The program uses counseling techniques delivered through a phone app. Researchers will enroll 120 adults with adv…

This study tests the DISCO app, designed to help cancer patients talk with their doctors about treatment costs. About 254 adults newly diagnosed with breast, prostate, lung, or colorectal cancer will use the app to become more confident in asking cost-related questions. The goal …

This study tests whether a supervised, home-based exercise program can help people with metastatic cancer who are starting oral targeted therapy. Participants are randomly assigned to either a weekly 60-minute session with a trained coach or to a booklet with exercise recommendat…

This trial tests Gelclair, a mouth rinse that forms a protective coating over the mouth's lining, to see if it eases the painful mouth sores (oral mucositis) caused by radiation therapy for head and neck cancer. The study enrolls adults with squamous cell carcinoma who will recei…

This study is testing whether a daily testosterone gel can reduce fatigue and improve sexual function in men aged 55 and older who have cancer and low testosterone. The trial involves 230 participants who will apply either the gel or a placebo for six months. Researchers will mea…

This study compares two ways of giving nutrition advice to cancer patients who have lost weight: video calls from home versus in-person hospital visits. Eighty adults with cancer and weight loss will receive personalized dietary counseling every two weeks for 12 weeks. The goal i…

This study looks at whether a structured educational program, added to usual care, can help people who have surgery for lung cancer. The goal is to see if it improves how well they accept their disease, their quality of life, and their pain levels. About 160 participants are spli…

This study looks at whether starting rehabilitation early or later helps reduce cancer-related fatigue in people with lung cancer. About 31 patients with stage II or III lung cancer will take part. The goal is to see if the rehab program is practical and helpful for improving ene…

This study tests whether wearing pressurized gloves and foot caps during chemotherapy can prevent nerve damage (peripheral neuropathy) caused by the drug paclitaxel. It involves 182 people with nasopharyngeal cancer who have not yet started treatment. Each patient serves as their…

This study tests whether a 12-week program of online chair-based exercise and health education, combined with a geriatric assessment, is feasible and helpful for adults aged 65+ with certain cancers and their support persons. The program is delivered remotely, and the study will …

This study tested a shorter course of high-dose radiation for people with stage IV lung cancer. The goal was to see if giving fewer, larger doses over fewer days could be as safe and effective as the standard longer schedule. 37 participants received radiation every other day for…

This study tests a new robotic surgery technique for stage I lung cancer. Instead of making cuts between the ribs, surgeons place the robot's tools below the ribcage. The goal is to see if this approach is safe and feasible, and if it can reduce pain and hospital stays. The trial…

This study aimed to see if a newer, daily-adaptive radiation technique could reduce coughing, breathing trouble, and swallowing pain in people with stage III non-small cell lung cancer getting chemo and radiation. It planned to compare the adaptive method to standard radiation. H…

This study tests two types of nerve blocks to control pain after lung surgery. About 28 adults having lung surgery will get either a Serratus Posterior Superior Intercostal Plane block or an Intercostal Nerve block. The goal is to see which block reduces pain, lowers the need for…

Researchers are building a large bank of blood and stool samples from people with advanced lung, breast, colorectal, and pancreatic cancers, plus healthy volunteers. The goal is to learn whether the mix of bacteria in a person's gut can predict how well cancer treatment works and…

This study tests whether reminder messages can encourage people aged 40-80 who smoke or have smoked to get screened for lung cancer. Researchers will ask about 133 participants how acceptable they find these reminders. The goal is to see if this simple approach could help more pe…

Researchers are building a bank of blood, urine, and stool samples from 100 adults with non-small-cell lung or colorectal cancer who are receiving checkpoint inhibitor immunotherapy. Over 12 months, participants provide five samples of each type. The goal is to study how the body…

This study is looking for biological markers (biomarkers) that might predict how well patients with certain types of squamous cell carcinoma respond to a type of immunotherapy called PD-1 inhibitors. Researchers will analyze blood and tumor tissue samples from 800 patients, both …

This study reviews medical records of 72 American Indian patients treated with immunotherapy for cancers like lung cancer, melanoma, and kidney cancer. Researchers compare their outcomes—such as how long the cancer is controlled and side effects—to those of White patients. The go…

This study looks at how patients with ALK-positive advanced non-small cell lung cancer respond to the drug lorlatinib when used as their first treatment in real-world settings. Researchers will analyze data from 200 patients in a U.S. database to see how long they stay on the dru…

This study tests whether giving smokers and former smokers a personalized risk report (based on clinical and genetic factors) helps doctors order lung cancer screening and helps patients follow through. About 915 participants will be randomly assigned to usual care or one of two …

Older adults with cancer who need intensive care often face a higher risk of dying, and delays in moving them from the emergency department to the ICU may add to that risk. This study reviews the medical records of 150 patients aged 65 and older with solid or blood cancers who we…

This study is testing whether regular screening for prostate, lung, colorectal, and ovarian cancers can reduce deaths from these diseases. About 154,900 men and women aged 55-74 were randomly assigned to either get screened or receive usual care. Researchers are tracking cancer c…

This study looks at whether new AI tools can make adaptive radiotherapy—adjusting radiation plans during treatment—faster and easier for people with advanced lung cancer. Researchers will measure how long each step takes and compare plan quality using standard CT scans versus dai…

This study looks at people and families who have a high risk of cancer to learn what genes and environmental factors might increase that risk. Over 5,000 participants are followed over time with questionnaires, medical records, and optional genetic testing. No treatment is given,…

This study aimed to evaluate how community cancer centers test for biomarkers in common solid cancers like breast, lung, and colorectal cancer. Researchers planned to survey pathology practices to see if they follow guidelines for key tests and how quickly results are reported. T…

This study tests a web-based education tool called HOPE-Genomics that teaches cancer patients about their genetic test results. About 465 adults with breast, colorectal, lung, ovarian, pancreatic, or prostate cancer are taking part. The goal is to see if the tool helps patients r…

This study will look back at medical records of about 1,000 people in the US with advanced non-small cell lung cancer who received a combination of the drug cemiplimab and chemotherapy as their first treatment. Researchers want to see how well the treatment works and what side ef…

This study is watching how patients with EGFR-mutated non-small cell lung cancer do when they receive standard treatment with osimertinib (Tagrisso) alone or with chemotherapy in routine medical practice. About 538 people with advanced lung cancer will be followed to see how long…

This study tests a low-literacy conversation tool designed to help lung cancer patients and their doctors make treatment decisions together. Researchers will enroll 300 patients to see if the tool improves understanding, reduces confusion, and boosts confidence in choices. The fo…

This trial studies whether small differences in genes affect how patients with small cell lung cancer respond to the chemotherapy drug etoposide and how severe its side effects are. Researchers will analyze DNA from 600 patients who take etoposide capsules, comparing two versions…

This study looks at how tiny genetic differences (called SNPs) in ALK-positive non-small cell lung cancer patients might influence how well the drug alectinib works and what side effects occur. Researchers will analyze DNA from 600 patients who have been taking alectinib for at l…

This study follows over 2,500 people with neuroendocrine tumors (NETs) to understand their symptoms and how treatments are chosen. Participants fill out surveys about quality of life and care experiences over 18 months. Researchers will link this to medical records to find which …

This study is collecting stool and blood samples from 120 advanced cancer patients receiving immunotherapy combinations. Researchers want to see if the types of bacteria in the gut and certain immune markers can predict which patients will develop serious side effects. The goal i…

This study looks back at medical records of children and young adults with solid tumors or lymphoma who also have a tumor thrombus—a blood clot that forms in a vein due to tumor pressure or invasion. Researchers will gather data on who received blood thinners or procedures like s…

This study explores whether a remote, direct-to-patient approach can improve how people with small cell lung cancer (SCLC) are reached and engaged in clinical research. It involves collecting biospecimens and surveying patients about their preferences and needs regarding new ther…

This study is testing whether regular blood tests that look for tumor DNA (called liquid biopsy) can help doctors make better treatment decisions for people with advanced colorectal or lung cancer. About 332 participants will be randomly assigned to either receive standard imagin…

This study looks at whether taking muco-active agents (mucus-thinning drugs like N-acetylcysteine and ambroxol) after a lung cancer diagnosis is linked to better outcomes in people who also have COPD. Researchers will analyze data from a large Korean database, comparing those who…

This study investigates whether bioimpedance analysis, a quick and painless test that measures body water and muscle mass using a weak electrical current, can help predict complications after lung cancer surgery. Researchers will compare these measurements with standard CT scans …

This study examines whether changes in the LKB1 gene can help predict how well people with non-small cell lung cancer respond to treatments like chemotherapy, targeted therapy, and immunotherapy. Researchers will analyze tumor samples and medical records from about 300 patients t…

This study looks at tumor samples from over 3,000 people with advanced cancers to find specific biomarkers—unique features of each cancer. The goal is to help doctors choose the most promising targeted therapy or clinical trial for each patient. Participants are adults with vario…

This study collects extra tissue and a small blood sample from people undergoing standard procedures for lung cancer. Researchers will use these samples to grow miniature versions of the tumors, called organoids, in the lab. The goal is to study how lung cancers grow and change, …

This study follows about 800 people with ALK-positive advanced non-small cell lung cancer who are taking the drug alectinib as part of their routine care. Researchers want to see how long the cancer stays under control and how patients are managed in real-world clinics, not just …

This study collects extra tissue samples from 200 people with advanced non-small cell lung cancer during routine biopsies. The goal is to train and validate a new diagnostic platform called Cybrid, which aims to predict how well a patient's tumor will respond to immunotherapy. Th…

This observational study collects extra tumor tissue from 416 people with various cancers (bladder, kidney, colorectal, head and neck, liver, lung, skin, endometrial) during routine biopsies. The goal is to develop and train a 'live tumor diagnostic platform' that can predict whe…

This phase 2 trial is testing how the immunotherapy drug pembrolizumab (Keytruda) changes immune-related genes and biomarkers in people with advanced solid tumors like head and neck cancer, triple-negative breast cancer, ovarian cancer, and melanoma. Researchers will analyze bloo…

This study looks at how frailty—a state of weakness and reduced physical function—affects the risk of severe side effects from chemotherapy in people aged 70 and older with cancer. Researchers will assess 160 patients using various tests for frailty, muscle loss, and overall heal…

This study tests a new way of organizing care for people aged 70 and older who have cancer (breast, lung, colorectal, or prostate) plus at least one other serious health condition. The GERONTE program brings all their doctors and nurses together using a shared digital care plan. …

This study observes how doctors in Russia treat inoperable lung cancer (NSCLC and SCLC) using chemoradiotherapy. Researchers will collect data from 2000 patients across 50 cancer centers to understand real-world practices and short-term outcomes. No new treatments are given; the …

This study is a long-term follow-up for 400 people who previously received A2 Bio gene therapy for various solid tumors, including colorectal, lung, pancreatic, and ovarian cancers. No new treatment is given; instead, researchers will track participants over time to check for del…

This study follows over 1,000 people with newly diagnosed non-small cell lung cancer in community cancer clinics. Researchers want to see how many patients receive key biomarker test results before starting treatment, and what barriers (like tissue issues or insurance problems) c…

This study looks at survival rates for people with cancers like melanoma, breast, colon, and lung cancer using data from Russian cancer registries. It includes 100,000 people of any age. The goal is to understand survival trends to help improve cancer care, not to test a new trea…

This study looks at the genetic makeup of lung cancers found through low-dose CT screening. Researchers want to understand why some cancers grow quickly and others grow slowly. About 526 people who had surgery for screen-detected lung cancer will provide tissue samples for DNA an…

This study follows over 1,800 adults who had early-stage lung cancer treatment to see how often they get CT scans and whether scanning every 6 months helps them live longer than yearly scans. Researchers will also check if scan frequency differs by race, income, or location. The …

This study aims to understand what factors help increase lung cancer screening in people aged 50-80 who smoke or have smoked. Researchers will track how many people get screened and interview staff and patients to learn what works. The goal is to improve screening rates and catch…

This study tracks 126 heavy smokers aged 50 to 74 in France to see how many complete a three-year lung cancer screening program using low-dose CT scans. Researchers also measure how many people quit smoking during the program. The goal is to understand real-world adherence, not t…

This study follows 814 people with early-stage non-small cell lung cancer to understand how the cancer evolves and spreads. Researchers collect tumor samples and medical data to see how genetic changes relate to treatment outcomes. The goal is to find ways to reduce the chance of…

This study compares two robotic platforms, DaVinci Xi and Versius, used in lung surgery to remove tumors or nodules. Researchers want to see if one leads to better recovery, fewer complications, or lower costs. About 150 patients having robotic lung surgery will answer quality-of…

This study follows 50 adults with ALK-positive non-small cell lung cancer who are taking brigatinib as their first treatment. Researchers want to see how long the cancer stays under control and how many patients respond to the drug in everyday hospital settings. No new treatment …

This study follows 446 people with stage I non-small cell lung cancer who chose either surgery or stereotactic body radiation therapy (SBRT). Researchers will track cancer recurrence, survival, and quality of life for up to 3 years to see which treatment offers better outcomes. T…

This study is looking for early signs of lung cancer in people at high risk, such as older smokers or those with COPD. Researchers will collect blood and airway samples from 665 participants to find biomarkers that could predict lung cancer before symptoms appear. The goal is to …

This study works with the Choctaw Nation to help more people get screened for lung cancer. Lung cancer is a leading cause of death in American Indian and Alaska Native communities, and screening can catch it early. The program will identify who is eligible, help them schedule and…

This study explores whether a simple breathing test done before surgery can help predict when a patient's oxygen levels might drop dangerously low during lung surgery. Researchers will measure how air moves through the lungs while patients breathe normally, then track oxygen leve…

This study looks at the bacteria living in the gut, lungs, and airways of 40 people with non-small cell lung cancer. Half receive surgery only, and half get chemotherapy before surgery. Researchers collect samples like blood, saliva, stool, and lung tissue to see how these bacter…

This study collects tumor tissue, blood, and saliva from 2500 people with various solid cancers to analyze their genetic makeup. The goal is to understand why some tumors become resistant to targeted therapies. Samples may also be grown in special mice to study how genetics affec…

This study examines how well immunotherapy works for people with both lung cancer and pulmonary fibrosis (scarred lungs). Researchers will compare 200 patients with both conditions to similar patients without scarring, tracking survival and side effects. They also analyze tumor t…

This study looks at how older adults (65+) with cancer understand their illness and what they value in life before and after a major operation. Researchers will interview 100 patients to learn about their awareness, expectations, and decision-making. No new drug or treatment is b…

This study follows 250 adults in Russia with advanced, inoperable non-small cell lung cancer who are receiving durvalumab after chemoradiation. Researchers will track side effects, treatment duration, and outcomes to see how the drug performs in routine clinical practice. The goa…

This study tests a new lab method called OPTin that helps doctors pick the most effective drugs for people with advanced or hard-to-treat solid tumors. About 200 adults will provide a small tumor sample for testing, then receive either a drug chosen by OPTin or one selected by th…

This study tests whether an electronic health record reminder (a 'nudge') can prompt doctors to order genetic tests for patients newly diagnosed with advanced non-small cell lung cancer. The goal is to have test results available before starting treatment, so doctors can choose t…

This early study tests whether using real-time MRI to guide radiation therapy is possible for people with advanced non-small cell lung cancer. The goal is to see if this personalized approach can reduce side effects and better control tumors. About 30 adults with stage III lung c…

This study checks how well a new MRI-guided radiotherapy machine works and how it fits into daily hospital routines. About 150 adults with solid tumors will take part. The goal is to see if the machine can be used smoothly for treatment, not to test a new cure.

This study looks at whether computer analysis of PET/CT scans can help doctors more accurately stage non-small cell lung cancer and predict genetic mutations. Researchers will use data from 500 patients to build and test machine learning models. The goal is to provide better, per…

This study tests whether a team of specialists (Molecular Tumor Board) can help choose better treatments for people with advanced lung cancer compared to usual care. About 659 participants with stage IIb-IV non-small cell lung cancer will be followed to see if the expert approach…

This study explores whether a special PET scan using a tracer called FAZA can detect low oxygen (hypoxia) in lung cancer tumors. Hypoxia can affect how tumors grow and respond to treatments like radiation. About 36 adults with stage II or III lung cancer will get one FAZA PET sca…

This study looks at how long Chinese patients with ALK-positive advanced lung cancer stay on brigatinib treatment in real-world settings. Researchers will also track cancer progression and response to the drug. About 154 participants are included, and the study simply observes th…

This study follows 160 lung cancer patients to see if their muscle mass, strength, and function are linked to how well they tolerate treatment and their overall survival. Researchers will also explore why some patients struggle to complete their therapy. The goal is to find ways …

This study looks at the stroma—the supportive tissue around tumors—in both benign and malignant growths. Researchers will examine 7,000 patient samples collected since 2000 at Brest University Hospital. The goal is to count non-tumor cells and measure matrix percentages in tumor …

This study tracks 1,000 people with advanced non-small cell lung cancer who are having surgery to remove lymph nodes. The goal is to see how often complications like nerve damage or bleeding happen and what factors make them more likely. By understanding these risks, doctors hope…

This study looks at whether special 4DCT scans can help doctors avoid damaging healthy lung tissue during radiation therapy for lung cancer. Researchers will compare standard radiation plans with ones that use lung function maps to spare well-working lung areas. The study uses ex…

This study looks at patients with non-small-cell lung cancer that has spread only to the brain (fewer than 5 spots). Researchers will review different treatment strategies used at two hospitals to see which leads to longer survival without the disease getting worse. The goal is t…

This study tests a new technology that adjusts the radiation beam in real time to follow lung tumors as they move with breathing. About 20 adults with early-stage lung cancer or limited lung metastases will receive standard radiotherapy with this tracking system. The main goal is…

This study will use advanced heart scans (coronary CT angiography) on 4,000 people with rheumatoid arthritis aged 50-75. The goal is to better understand why people with this condition have higher risks of heart attacks, strokes, and lung problems. Researchers will track particip…

This observational study aims to create a national registry of genetic mutations found in advanced solid tumors. By collecting data from over 2,000 Italian patients, researchers hope to improve access to innovative therapies. The study does not test a new treatment but gathers in…

This study tests a new X-ray technique to track lung tumors during radiation without needing implanted markers. Five adults with early-stage lung cancer will be observed to see if the markerless method matches the standard marker-based tracking within 3 millimeters. If it works, …

This study is observing how well a combination of two immunotherapy drugs (nivolumab and ipilimumab) works for people with advanced non-small cell lung cancer in Italy. Researchers are collecting data from 404 patients to understand real-world outcomes, side effects, and treatmen…

This study looks at whether a computer model can analyze routine brain MRI scans to predict if a lung cancer that has spread to the brain has certain genetic changes (EGFR or ALK). The goal is to see if this noninvasive method can replace the need for a brain tumor biopsy to guid…

This study looks at how the immune system changes in 45 people with stage III non-small cell lung cancer who receive chemoradiation followed by the drug durvalumab. Researchers want to find immune markers that could predict how well the treatment works. The goal is to improve fut…

This study looks at the best way to collect tissue samples from lung cancer patients using a thin tube passed through the mouth (endobronchial ultrasound). It compares taking 2 versus 3 samples from each lymph node to see if fewer samples still provide enough material for genetic…

This study tests whether artificial intelligence (AI) can help doctors find and describe lung nodules on CT scans. Lung nodules can be a sign of early-stage lung cancer, but telling harmless ones from dangerous ones is hard. The AI will learn from 329 adults' CT images and biopsy…

This study looks at whether having low muscle mass (sarcopenia) before lung cancer surgery affects how well patients recover. Researchers will follow 400 older adults having lung cancer surgery to see if sarcopenia is linked to survival and other outcomes. The goal is to find out…

This study looks at a specific DNA repair issue called homologous recombination deficiency (HRD) in people with a type of lung cancer (EGFR-mutated NSCLC). Researchers want to know how common HRD is and whether it relates to how the cancer behaves. They will also test this in lab…

This study tests two simple approaches to help people stick with annual lung cancer screening: automated reminders for doctors and patients, plus an educational video. About 1,837 adults aged 50-78 who already had a negative scan are taking part at Kaiser Permanente Washington. T…

This study looks at 400 people who had surgery to remove throat cancer (laryngectomy or pharyngolaryngectomy). The goal is to find out which factors, like using a surgical flap or muscle loss (sarcopenia), increase the risk of a fistula—a leak that can cause infection. Researcher…

This study compares two ways of doing a lung biopsy (EBUS) for people with known or suspected non-small cell lung cancer. In one group, a cytotechnologist checks the tissue sample on-site during the procedure to give feedback. In the other group, no on-site check is done. The goa…

This study brings together cancer experts to agree on standard definitions for key measurements used in cancer clinical trials, such as how long patients live without their cancer getting worse. Currently, different trials define these measurements in different ways, making it ha…

This study looks at whether tiny particles called exosomes, found in blood and lung fluid, can predict how well treatment works in advanced lung cancer patients with fluid buildup around the lungs. Researchers will collect samples from 100 patients before and during standard ther…

This study observes how the drug osimertinib works in real-life settings for people with advanced lung cancer that has a specific genetic change (EGFR mutation). About 274 adults in France will be followed for up to 3 years to see how long they live, how their disease changes, an…

This study looks at whether food preferences can help predict undernutrition in people with stage IV non-small cell lung cancer who are starting their first treatment. About 190 participants will have their food cravings measured and receive personalized dietary advice if needed.…

This study looks at whether a special decision-making tool can help doctors and patients with advanced non-small cell lung cancer decide when to stop cancer treatments. The goal is to reduce the number of patients receiving chemotherapy or other treatments in their last days of l…

This study looks at whether certain inherited gene changes (EGFR mutations) increase the risk of lung cancer, especially in people who never smoked. Researchers collect saliva from cancer patients with a specific tumor mutation (T790M) to find these inherited changes. They also o…

This study tests whether a remote monitoring system—including a smartphone app, a Fitbit, and a smart pill cap—can effectively track symptoms and side effects in 30 lung cancer patients taking oral targeted therapy. Participants will use the system for up to 24 weeks, and the goa…

This study is looking at 100 people with stage IIIA lung cancer who are getting treatment before surgery. Researchers want to see if a blood test that looks for tumor DNA (ctDNA) can predict how well patients do. If the tumor DNA disappears after treatment, it might mean a better…

This study looks at how the diversity of bacteria in the gut might affect how well immunotherapy works in people with solid tumors. Researchers will collect stool and blood samples from 70 cancer patients starting immunotherapy to track changes in gut bacteria and immune markers.…

This registry is collecting blood samples and health data from 400 people with neuroendocrine tumors. The goal is to see if a new blood test called NETest can help detect tumor activity and predict disease progression. Participants include patients before and after surgery, those…

This study looks at whether bacteria in the gut and throat can predict how well stage III lung cancer patients respond to the immunotherapy drug durvalumab after chemoradiation. Researchers will collect stool, throat swabs, and breath samples from 126 participants to see if these…

This study looks at 80 lung cancer patients with complex conditions, like rare tumor types or previous radiation, to see how well radiotherapy works and what side effects occur. The goal is to gather information to help doctors make better treatment decisions for future patients.…